Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730193 · ClinicalTrials.gov registry record · Early Phase 1
Caffeine and Cerebrovascular Reactivity
A Early Phase 1 study of Caffeine, sponsored by University of Oklahoma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04730193: Completed Early Phase 1 study of Caffeine, sponsored by University of Oklahoma.
NCT04730193 is a Early Phase 1 study of Caffeine that has completed, run by University of Oklahoma. The registered enrollment target is 10 participants, below the 74-participant average among 6 other Caffeine trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04730193, a Early Phase 1 study of Caffeine, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.
Primary Outcome
Caffeine Research Visual Analogue Scales consists of seven visual analogue scales ("relaxed", "alert", "jittery", "tired", "tense", "headache", overall mood") are measured from 1 to 10 and have previously been used in research to evaluate the effects of caffeine. A single "mentally fatigued" visual analogue scale (scored from 1 to 10) will be included, as previous research has shown it to be sensitive to a caffeine-glucose drink.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Caffeine
Study Locations (1)
Oklahoma
- Translational GeroScience Laboratory - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2022-08-01 |
| Phase | Early Phase 1 |
What the finished NCT04730193 record still lists
NCT04730193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 74-participant average among 6 other Caffeine trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Caffeine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04730193 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04730193 about?
NCT04730193 is a clinical study titled "Caffeine and Cerebrovascular Reactivity". Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow ...
What is the current status of trial NCT04730193?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2021-02-01. Estimated completion is 2022-08-01.
What conditions does trial NCT04730193 study?
This clinical trial studies the following conditions: Caffeine.
What interventions are being tested in trial NCT04730193?
The interventions under investigation include: Placebo (DRUG), Caffeine (DRUG).
Who is sponsoring clinical trial NCT04730193?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04730193 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Caffeine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Caffeine Optimization Versus Standard Caffeine Dosage (2B-2)
RECRUITING · NA
-
Effects of Variations in Caffeinated Beverages on Well-being
RECRUITING · NA
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Effects of Caffeinated Beverages on Well-being
RECRUITING · NA
-
Early Versus Routine Caffeine Administration in Extremely Preterm Neonates
COMPLETED · Phase 4
-
Effects of a Cocoa Shot on the Human Brain
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI